TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19393843
Drug: MO infusion
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MO infusion (10 microg/kg/h) + BUP boluses (0.15 microg/kg)
Study: 9882760
Drug: Temazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (20 mg p.o.)
Study: 7721974
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg nitroglycerin (LDG)
Study: 7721974
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg nitroglycerin (HDG)
Study: 2199853
Drug: Ciclopiroxolamine globules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopiroxolamine globules, 100 mg nightly for six days
Study: 2199853
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal tablets, 200 mg nightly for six days
Study: 7014121
Drug: Oral propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol, 40 mg
Study: 11006450
Drug: Ceftibuten 9
Normalized name: ceftibuten 90 MG in 5 mL Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 9 mg/kg/day for 5 days
Study: 11006450
Drug: Ceftibuten 9
Normalized name: ceftibuten 90 MG in 5 mL Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 9 mg/kg/day for 10 days
Study: 8839497
Drug: Cereal-based precooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal-based precooked porridge offered twice daily for 3 months (558-790 kJ/d)
Study: 6436891
Drug: 195 mg
Normalized name: aspirin 195 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 195 mg caffeine
Study: 3555083
Drug: 10 IU
Normalized name: Thyrotropin 10 IU Injection Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 IU of oxytocin in 10 ml of sodium chloride into the umbilical vein
Study: 3555083
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of sodium chloride
Study: 17081363
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Control, n = 25)
Study: 12823568
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with antiepileptic drugs (AEDs)
Study: 12823568
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring for dosage tailoring
Study: 12823568
Drug: Newer antiepileptic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antiepileptic agents
Study: 12823568
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine and treatment guidelines
Study: 12823568
Drug: Patient-tailored AED
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-tailored AED selection and dose individualization
Study: 12823568
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy in refractory epilepsies
Study: 12823568
Drug: Novel antiepileptic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel antiepileptic drugs
Study: 1430302
Drug: Surface electrocardiogram
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface electrocardiogram 2 hours after dose administration
Study: 27329780
Drug: Pretreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with antifungal agents
Study: 22202581
Drug: Whole-cell melanoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell melanoma vaccine (Canvaxin) plus Bacille Calmette-Guerin (BCG)
Study: 20860537
Drug: Extra water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra water intake (EWI, an additional 30 ml water/kg body weight per day)
Study: 10891628
Drug: Clozapine 12.5
Normalized name: clozapine 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 12.5 mg
Study: 10891628
Drug: Clozapine 25
Normalized name: clozapine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 25 mg
Study: 10891628
Drug: Clozapine 50
Normalized name: clozapine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 50 mg
Study: 8752234
Drug: Atosiban (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (0.6 mg plus 30 micrograms/minute)
Study: 8752234
Drug: Atosiban (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (6.5 mg bolus plus 300 micrograms/minute)
Study: 1362394
Drug: dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: dopamine agonists
Study: 1362394
Drug: l-deprenyl
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-deprenyl
Study: 3891617
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg oral)
Study: 20350164
Drug: Fractional-dose IPV
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional-dose IPV (0.1 mL, or 1/5 of a full dose) given intradermally
Study: 20350164
Drug: Full-dose IPV
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose IPV given intramuscularly
Study: 12709724
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 200 mg twice daily for 10 days
Study: 12709724
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 400 mg twice daily for 14 days
Study: 26790793
Drug: Systemic Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic Tranexamic Acid (TXA) 15 mg/kg before and 10 mg/kg 1 hour after surgery
Study: 26790793
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid (TXA) 2 g
Study: 23168135
Drug: Backfill with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Backfill with hydroxyapatite-calcium triphosphate (HCT) biphasic compound
Study: 16990664
Drug: GAD65 antibody
Normalized name: Recombinant human GAD65
DrugBank: rhGAD65 (DB04963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD65 antibody response
Study: 12809069
Drug: Parenteral piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral piracetam treatment
Study: 12809069
Drug: Traditional meprobamat
Normalized name: Meprobamat
DrugBank: Meprobamate (DB00371)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional meprobamat therapy
Study: 11014392
Drug: S-Caine patch
Normalized name: Comfort Caine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Caine patch coupled with a controlled heat-aided drug delivery (CHADD) patch
Study: 9483483
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate therapy (Group I)
Study: 9483483
Drug: No magnesium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No magnesium treatment (Group II)
Study: 2751854
Drug: Ranitidine (H2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (H2 antagonist)
Study: 326482
Drug: Practolol (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (dose up to 800 mg daily)
Study: 326482
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration of practolol
Study: 31860328
Drug: Standard 6‐month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 6‐month course of tuberculosis treatment (180 days), dosed every other day (90 doses)
Study: 30380221
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg · kg⁻¹ loading dose for 10 min, followed by 0.7 μg · kg⁻¹ · hr⁻¹ maintenance)
Study: 30380221
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 μg · kg⁻¹ loading dose, followed by 1-2 μg · kg⁻¹ · hr⁻¹ maintenance)
Study: 21643812
Drug: Atorvastatin (intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (intensive lipid-lowering therapy for 6 months)
Study: 21643812
Drug: Pravastatin (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (moderate lipid-lowering therapy for 6 months)
Study: 17301737
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2.5 mg tibolone
Study: 17301737
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of tibolone (placebo, 0.3, 0.625, 1.25, or 2.5 mg/day for 26 cycles of 28 days)
Study: 11304601
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream 1.5 g/10 cm2 applied for 2 to 5 hours
Study: 11304601
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream 3 g/10 cm2
Study: 11304601
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events (EMLA cream)
Study: 1279611
Drug: Verapamil (120-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120-mg thrice daily)
Study: 1279611
Drug: Diltiazem (60-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60-mg thrice daily)
Study: 2936269
Drug: Papaveretum 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum 0.4 mg/kg
Study: 2936269
Drug: Hyoscine 0.008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine 0.008 mg/kg
Study: 22395587
Drug: 8% and
Normalized name: SULFACETAMIDE SODIUM 80 mg in 1 mL / SULFUR 40 mg in 1 mL TOPICAL SUSPENSION [Sodium Sulfacetamide 8% and Sulfur 4%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% and 10% topical sulfur ointment applied for a single day (24 hours)
Study: 22395587
Drug: 8% and
Normalized name: SULFACETAMIDE SODIUM 80 mg in 1 mL / SULFUR 40 mg in 1 mL TOPICAL SUSPENSION [Sodium Sulfacetamide 8% and Sulfur 4%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% and 10% topical sulfur ointment applied for three successive nights
Study: 22395587
Drug: 8% and
Normalized name: SULFACETAMIDE SODIUM 80 mg in 1 mL / SULFUR 40 mg in 1 mL TOPICAL SUSPENSION [Sodium Sulfacetamide 8% and Sulfur 4%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% and 10% topical sulfur ointment applied for three successive days
Study: 19965971
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of heparin and aspirin
Study: 16735113
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 micro g bd
Study: 16735113
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 200 micro g bd
Study: 9863300
Drug: Beta-interferon (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-interferon (subcutaneous or intramuscular administration)
Study: 8705152
Drug: Intranasal nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nitroglycerin 0.3 mg
Study: 8705152
Drug: Intranasal nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nitroglycerin 0.5 mg
Study: 8705152
Drug: Intranasal nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nitroglycerin 0.75 mg
Study: 8705152
Drug: Intranasal nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nitroglycerin 1.0 mg
Study: 7033016
Drug: Benzbromarone 100
Normalized name: benzbromarone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone 100 mg daily
Study: 7033016
Drug: Probenecid 1000
Normalized name: probenecid 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid 1000 mg daily
Study: 30794093
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) + Driving-based interactive video games (DBIVG)
Study: 30794093
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) + Treadmill walking training
Study: 2696020
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg iron daily
Study: 31658725
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg iron daily
Study: 31658725
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iron daily
Study: 29202732
Drug: Targeted kyphosis-specific
Normalized name: Kyprolis
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Targeted kyphosis-specific exercise and posture training program, delivered by a physical therapist, 1 hour, twice a week for 3 months.
Study: 25324445
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and ondansetron
Study: 23887167
Drug: Hecolin (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hecolin (recombinant hepatitis E vaccine)
Study: 21538380
Drug: VASP-guided clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: VASP-guided clopidogrel maintenance doses
Study: 21538380
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with fixed clopidogrel doses
Study: 11301563
Drug: BMS-188494 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-188494 (10 mg daily for 2 weeks)
Study: 11301563
Drug: BMS-188494 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-188494 (25 mg daily for 4 weeks)
Study: 11301563
Drug: BMS-188494 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-188494 (50 mg daily for 4 weeks)
Study: 11301563
Drug: BMS-188494 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-188494 (100 mg daily for 4 weeks)
Study: 11301563
Drug: BMS-188494 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-188494 (200 mg daily for 4 weeks)
Study: 11301563
Drug: BMS-188494 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-188494 (all doses)
Study: 2848876
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no active agents)
Study: 16537882
Drug: Intrapleural fibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural fibrinolytic therapy
Study: 11139755
Drug: NSAIDs (ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ibuprofen 400-800mg, naproxen 550-825mg, ketoprofen 50-75mg)
Study: 11139755
Drug: Caffeine-containing preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing preparations of NSAIDs
Study: 11139755
Drug: Relaxation therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapies with EMG biofeedback and tricyclics
Study: 11139755
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and acupuncture
Study: 8864328
Drug: Pantoprazole 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 240 mg i.v. once daily for 7 days
Study: 1623916
Drug: Loperamide oxide
Normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide oxide (1 to 16 mg)
Study: 6391141
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg twice weekly for 1 year)
Study: 26825878
Drug: Liposomal Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Albendazole (L‐ABZ), 10 mg/kg per day, p.o., b.i.d.
Study: 26825878
Drug: Tablet-Albendazole (T‐ABZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-Albendazole (T‐ABZ), 12-20 mg/kg per day, p.o., b.i.d.
Study: 26825878
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L‐ABZ and T‐ABZ)
Study: 20578811
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER 100 ‐ 250 mg b.i.d.
Study: 20578811
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR 20 ‐ 50 mg b.i.d.
Study: 12352272
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (15-mg nicotine patch, 4-mg nicotine gum, 10-mg nicotine inhaler, or combination)
Study: 7750335
Drug: Control (face‐mask
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (face‐mask oxygen therapy)
Study: 2184356
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n = 51)
Study: 7292376
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg twice daily for three weeks
Study: 31197389
Drug: Arthroscopic lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic lateral ligaments augmentation using suture-tape internal bracing (AST)
Study: 27136907
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 100 mg eq. (156 mg of PP) administered via deltoid injections
Study: 27136907
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 100 mg eq. (156 mg of PP) administered via gluteal injections
Study: 21991738
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injection plus rehabilitation program
Study: 12615585
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1.5 micro g/kg)
Study: 12615585
Drug: Nebulized fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized fentanyl (1.5 micro g/kg)
Study: 10848718
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg daily for 8 days)
Study: 9313642
Drug: rTMS over
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS over other positions (e.g. F3, F4, FCz, P3, P4)
Study: 2878130
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment during the trial
Study: 31350814
Drug: Purgenesis™ Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purgenesis™ Day Cream, Purgenesis™ Eye Cream, and Purgenesis™ Night Cream
Study: 31350814
Drug: Prevage® Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevage® Eye Lotion, Prevage® Day Cream, and Prevage® Night Cream
Study: 31350814
Drug: La Mer®
Approvals — FDA: no, EMA: no, PMDA: no
Description: La Mer® Eye Balm, Crème de La Mer®, and La Mer® Night Cream
Study: 29494818
Drug: Extended nodal
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Iodal HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel 135 mg/m2 day 1 and cisplatin 20 mg/m2 days 1‐3, every 4 weeks) plus erlotinib (150 mg per day during chemoradiotherapy)
Study: 29494818
Drug: Extended nodal
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Iodal HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy
Study: 29494818
Drug: Conventional field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy plus erlotinib
Study: 29494818
Drug: Conventional field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy
Study: 24374549
Drug: Semuloparin 20
Normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semuloparin 20 mg commenced postoperatively
Study: 24374549
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg commenced preoperatively
Study: 20602568
Drug: PEG +
Normalized name: Polyethylene glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG + Asc (2 l PEG + ascorbic acid)
Study: 20602568
Drug: PEG (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG (4 l PEG solution)
Study: 16633762
Drug: Intravenous propofol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propofol, fentanyl, and vecuronium anesthesia (TIVA, n = 30)
Study: 16633762
Drug: Intravenous propofol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propofol, fentanyl, and vecuronium anesthesia (TIVA)
Study: 11729013
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of paroxetine
Study: 11729013
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of paroxetine
Study: 3069498
Drug: Intra-arterial instillation
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial instillation of 0.5 mg reserpine
Study: 19008680
Drug: Cognitive-linguistic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-linguistic treatment
Study: 16785475
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg body weight, once-monthly infusion)
Study: 10955205
Drug: 7 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 treatment groups with different kinds of tutor modeling (whole word, letter-phoneme, combined whole word and letter-phoneme)
Study: 8251355
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg at night
Study: 3513564
Drug: Oral metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metaproterenol